Format

Send to

Choose Destination
J Am Acad Dermatol. 2007 Apr;56(4):604-11. Epub 2007 Feb 15.

Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.

Author information

1
University of California Los Angeles School of Medicine, USA. cranleyuk@aol.com

Abstract

BACKGROUND:

The long-term effects of botulinum toxin type A (BoNTA) on the global impairment associated with severe primary axillary hyperhidrosis have not been comprehensively assessed relative to placebo.

OBJECTIVE:

To assess the efficacy and safety of 2 dosages of BoNTA compared with placebo in subjects with primary axillary hyperhidrosis.

METHODS:

Subjects (N = 322) were randomized to the use of BoNTA (75 U or 50 U/axilla) or placebo in this 52-week, multicenter, double-blind study.

RESULTS:

BoNTA treatment significantly reduced daily activity limitations at 4 weeks after injection. A 2-point improvement on the 4-point Hyperhidrosis Disease Severity Scale (HDSS) was reported in 75% of subjects in the 75-U and 50-U BoNTA groups and in 25% of the placebo group (P < .001). Improvements in HDSS scores were corroborated by gravimetric results. The median duration of effect was 197 days, 205 days, and 96 days in the 75-U, 50-U, and placebo groups, respectively. BoNTA was well tolerated.

LIMITATIONS:

The effect of total surface area involvement on treatment efficacy was not evaluated.

CONCLUSION:

BoNTA treatment effectively reduces the symptoms of primary axillary hyperhidrosis and is well tolerated.

PMID:
17306417
DOI:
10.1016/j.jaad.2007.01.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center